Adolescent development and SLE

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 2, 2006, Pages 353-368

  Beresford, Michael W ^a   Davidson, Joyce E ^b  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Adolescence; Disease activity; Outcome; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; RITUXIMAB;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANTIPHOSPHOLIPID SYNDROME; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG MEGADOSE; EARLY DIAGNOSIS; HAIR DISEASE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; IMMUNOPATHOLOGY; INFERTILITY; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MORBIDITY; MORTALITY; NAUSEA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK BENEFIT ANALYSIS; SEXUAL HEALTH; SIDE EFFECT; SOCIAL PSYCHOLOGY; STRIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UTERINE CERVIX DYSPLASIA; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT DEVELOPMENT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATIENT COMPLIANCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644982201     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.11.003     Document Type: Review

References (74)

1. P. Youinou P.M. Lydyard R.A. Mageed B cells underpin lupus immunopathology Lupus 11 2002 1-3
2. M. Bijl P.C. Limburg C.G.M. Kallenberg New insights into the pathogenesis of systemic lupus erythematosus (SLE): The role of apoptosis The Netherlands Journal of Medicine 59 2001 66-75
3. L.B. Tucker S. Menon J.G. Schaller et. al. Adult- and childhood-onset systemic lupus erythematosus: A comparison of onset, clinical features, serology and outcome British Journal of Rheumatology 34 1995 866-872
4. L.-C. Wang Y.-H. Yang M.-Y. Lu et. al. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades Journal of Microbiology Immunology and Infection 36 2003 203-208
5. P.M. Miettunen O. Ortiz-Alvarez R.E. Petty et. al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus The Journal of Rheumatology 31 2004 1650-1654
6. S. Janwityanujit K. Totemchokchyakarn O. Versertniyom et. al. Age-related differences on clinical and immunological manifestations of SLE Asian Pacific Journal of Allergy and Immunology 13 1995 145-149
7. I. Pande N.G. Sekharan S. Kailash et. al. Analysis of clinical and laboratory profile in Indian childhood systemic lupus erythematosus and its comparison with SLE in adults Lupus 2 1993 83-87
8. D. Stichweh E. Arce V. Pascual Update on pediatric systemic lupus erythematosus Current Opinion in Rheumatology 16 2004 577-587
9. M.W. Beresford A.G. Cleary J.A. Sills et. al. Cardiopulmonary involvement in juvenile systemic lupus erythematosus Lupus 14 2005 152-158
10. G.C. Tsokos G.M. Kammer Molecular aberrations in human systemic lupus erythematosus Molecular Medicine Today 6 2000 418-424
11. B.P. Tsao D.J. Wallace Genetics of systemic lupus erythematosus Current Opinion in Rheumatology 9 1997 377-379
12. J.E. McDonagh The adolescent challenge Nephrology, Dialysis, Transplantation 15 2000 1761-1765
13. H.I. Brunner E.H. Gianni Health-related quality of life in children with rheumatic diseases Current Opinion in Rheumatology 15 2003 602-612
14. M.C. Hochberg Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis and Rheumatism 40 1997 1725
15. E.M. Tan A.S. Cohen J.F. Fries et. al. The revised criteria for the classification of systemic lupus erythematosus Arthritis and Rheumatism 25 1982 1271-1277
16. M.B. Ferraz J. Goldenberg M.O. Hilario et. al. Evaluation of the ARC lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology Clinical and Experimental Rheumatology 12 1994 689-690
17. J.D. Shulman Prevalence of oral mucosal lesions in children and youths in the USA International Journal of Paediatric Dentistry 15 2005 89-97
18. M.O. Hilario C.A. Len S.C. Roja et. al. Frequency of antinuclear antibodies in healthy children and adolescents Clinical Pediatrics 43 2004 637-642
19. F. Cainelli C. Betterle S. Vento Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus Annals of the Rheumatic Diseases 63 2004 1707-1708
20. S.A. Zimmerman R.E. Ware Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenia purpura Journal of Pediatric Hematology/Oncology 19 1997 297-303
21. D.P. Symmons J.S. Coppock P.A. Bacon et. al. Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG) Quarterly Journal of Medicine 69 1988 927-937
22. D.A. Isenberg A. Rahman E. Allen et. al. BILAG 2004: Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus Rheumatology 44 2004 902-906
23. N. Ruperto A. Ravelli K.J. Murray et. al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis Rheumatology 42 2003 1452-1459
24. N. Ruperto A. Ravelli R. Cuttica et. al. The Pediatric Rheumatology International Trials Organisation criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set Arthritis and Rheumatism 52 2005 2854-2864
25. H.I. Brunner O.Y. Jones D.J. Lovell et. al. Lupus headaches in childhood-onset systemic lupus erythematosus: Relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage Lupus 12 2003 600-606
26. S.D. Marks C. Pilkington P. Woo et. al. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus Rheumatology 43 2004 1186-1189
27. L.J. Haines G. Saidi R.W. Cooke Prevalence of severe fatigue in primary care Archives of Disease in Childhood 90 2005 367-368
28. M.O. Olfat S.M. Al-Mayouf M.A. Muzaffer Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus Clinical Rheumatology 23 2004 395-399
29. P.M. Wyckoff L.C. Miller L.B. Tucker et. al. Neuropsychological assessment of children and adolescents with systemic lupus erythematosus Lupus 4 1995 217-220
30. The American College of Rheumatology. Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and Rheumatism 1999; 42: 599-608.
31. M. Govoni G. Castellino M. Padovan et. al. Recent advances and future perspectives in neuroimaging in neuropsychiatric systemic lupus erythematosus Lupus 13 2004 149-158
32. F. Falcini M.T. De Cristofaro M. Ermini et. al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: A prospective SPECT study The Journal of Rheumatology 25 1998 583-588
33. J.G. Hanly M.J. Harrison Management of neuropsychiatric lupus Best Practice and Research Clinical Rheumatology 19 2005 799-821
34. D.T. Hsu Biological and psychological differences in the child and adolescent transplant recipients Pediatric Transplantation 9 2005 416-421
35. D.H. McDaniel Laser therapy of stretch marks Dermatologic Clinics 20 2002 67-76
36. F.A. Houssiau C. Vasconcelos D. D'Cruz et. al. Immunosuppressive therapy in lupus nephritis: The European Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose cyclophosphamide Arthritis and Rheumatism 46 2002 2121-2131
37. J. Cross A. Dwomoa P. Andrews et. al. Mycophenolate mofetil for remission induction in severe lupus nephritis Nephron Clinical Practice 100 2005 92-100
38. T.M. Chan F.K. Li C.S. Tang et. al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative nephritis. Hong Kong-Guangzhou Nephrology Study Group The New England Journal of Medicine 343 2000 1156-1162
39. T.M. Chan K.C. Tse C.S. Tang et. al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis Journal of the American Society of Nephrology 16 2005 1076-1084
40. S. Buratti I.S. Szer C.H. Spencer et. al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus Rheumatology 28 2001 2103-2108
41. P.P. Sfikakis J.N. Boletis G.C. Tsokos Rituximab anti-B cell therapy in systemic lupus erythematosus: Pointing to the future Current Opinion in Rheumatology 17 2005 550-557
42. M. Edelbauer T. Jungraithmayr L.B. Zimmerhackl Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: Case report Pediatric Nephrology 20 2005 811-813
43. D. Jayne J. Passweg A. Marmont et. al. Autologous stem cell transplantation for systemic lupus erythematosus Lupus 13 2004 168-176
44. C.A. Silva M.M. Leal C. Leone et. al. Gonadal function in adolescent and young women with juvenile systemic lupus erythematosus Lupus 11 2002 419-425
45. L. Huong du Z. Amoura P. Duhaut et. al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. a study of 84 patients The Journal of Rheumatology 29 2002 2571-2576
46. P. Riley S.M. Maillard L.R. Wedderburn et. al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety Rheumatology 43 2004 491-496
47. C.A. Silva J. Hallak F.F. Pasqualotto et. al. Gonadal dysfunction in male adolescents and young males with juvenile onset systemic lupus erythematosus The Journal of Rheumatology 29 2002 2000-2005
48. L. Lakasing M. Khamashta Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: What advice should we be giving? The Journal of Family Planning and Reproductive Health Care 27 2001 7-12
49. V.M. Ognenovski W. Marder E.C. Somers et. al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide The Journal of Rheumatology 31 2004 1763-1767
50. K.E. Moss Y. Iaonnou S.M. Sultan et. al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for two decades Annals of the Rheumatic Diseases 61 2002 409-413
51. L.B. Tucker Controversies and advances in the management of systemic lupus eryhtematosus in children and adolescents Best Practice and Research Clinical Rheumatology 16 2002 471-480
52. H.I. Brunner E.D. Silverman T. To et. al. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage Arthritis and Rheumatism 46 2002 436-444
53. H.I. Brunner B.M. Feldman M.B. Urowitz et. al. Item weightings for the systemic lupus erythematosus international collaborating clinics/ American College of Rheumatology disease damage index using Rasch analysis do not lead to an important improvement The Journal of Rheumatology 30 2003 292-297
54. D.D. Gladman M.B. Urowitz The SLICC/ACR damage index: Progress report and experience in the field Lupus 8 1999 632-637
55. T. Stoll B. Seifert D.A. Isenberg SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus British Journal of Rheumatology 35 1996 248-254
56. P. Rahman D.D. Gladman M.B. Urowitz et. al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus Lupus 10 2001 93-96
57. T. Stoll N. Sutcliffe J. Mach et. al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study Rheumatology 43 2004 1039-1044
58. L.N. Moorthy L. Robbins M.J. Harrison et. al. Quality of life in paediatric lupus Lupus 13 2004 234-240
59. K.P. Leong K.O. Kong B.Y.H. Thong et. al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL) Rheumatology 44 2005 1267-1276
60. S. Rinaldi A. Doria F. Salaffi et. al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age Rheumatology 43 2004 1574-1579
61. A. Doria S. Rinaldi M. Ermani et. al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants Rheumatology 43 2004 1580-1586
62. S. Khanna H. Pal R.M. Pandey et. al. The relationship between disease activity and quality of life in systemic lupus erythematosus Rheumatology 43 2004 1536-1540
63. J. Wajed Y. Ahmed P.N. Darlington et. al. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management Rheumatology 43 2004 7-12
64. J.M. Esdaile M. Abrahamowicz T. Grodzicky et. al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus Arthritis and Rheumatism 44 2001 2331-2337
65. M.B. Urowitz M. Feletar I.N. Bruce et. al. Prolonged remission in systemic lupus erythematosus The Journal of Rheumatology 32 2005 1467-1472
66. B.J. Fessler G.S. Alarcóon G. McGwin et. al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual Arthritis and Rheumatism 52 2005 1473-1480
67. E.C. Jury M.R. Ehrenstein Statins: Immunomodulators for autoimmune rheumatic disease? Lupus 14 2005 192-196
68. S. Lakshminarayanan S. Walsh M. Mohanraj et. al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus The Journal of Rheumatology 28 2001 102-108
69. C.-S. Yee N. Crabtree J. Skan et. al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus Annals of the Rheumatic Diseases 64 2005 111-113
70. I.E.M. Bultink W.F. Lems P.J. Kostense et. al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus Arthritis and Rheumatism 54 2005 2044-2050
71. S. Trapani R. Civinini M. Ermini et. al. Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study of the effect of steroids on bone mineral density Rheumatology International 18 2001 45-49
72. P.P. Geusens R.N.J. de Nijs W.F. Lems et. al. Prevention of glucocorticoid osteoporosis: A consensus document of the Dutch society for Rheumtology Annals of the Rheumatic Diseases 63 2004 324-325
73. P.N. Sambrook How to prevent steroid induced osteoporosis Annals of the Rheumatic Diseases 64 2005 176-178
74. Royal College of Paediatrics and Child Health. Bridging the gaps. Healthcare for adolescents; 2003.